Rebecca A Previs

Adjunct Assistant Professor in the Department of Obstetrics and Gynecology · 2022 - Present Obstetrics and Gynecology, Gynecologic Oncology, Obstetrics and Gynecology

Member of the Duke Cancer Institute · 2018 - Present Duke Cancer Institute, Institutes and Centers

In the News

Published April 8, 2022

Findings Support Retesting for MMRD at Uterine Cancer Recurrence

Published December 1, 2021

Dissecting Disparities in Cancer Outcomes

Published May 3, 2019

Urogynecology, Gynecologic Oncology Faculty Receive Research Awards

View All News

Recent Publications

Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.

Journal Article Neoplasia · November 2024 Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor and immune stimulatory effects of an on ... Full text Link to item Cite

Data from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <div>Abstract<p>Triple-negative breast cancers (TNBCs) tend to become invasive and metastatic at early stages in their development. Despite some treatment successes in early stage localized TNBC, the rate of distant recurrence remains h ... Full text Cite

Supplementary Figures 1-4 and Tables 1-2 from Targeting CaMKK2 inhibits actin cytoskeletal assembly to suppress cancer metastasis

Other · September 16, 2024 <p>Contains Supplementary Figures 1-4, Supplementary Tables 1-2 and legends for Supplementary Videos 1-4</p> ... Full text Cite

View All Publications

Recent Grants

Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer

Clinical TrialSignificant Contributor · Awarded by National Institutes of Health · 2014 - 2023

Use of an oncolytic adenovirus to promote anti-tumor T-cell responses in ovarian cancer

ResearchMentor · Awarded by Foundation for Women's Cancer · 2022 - 2023

Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy

ResearchPrincipal Investigator · Awarded by Ponce Health Sciences University · 2020 - 2022

View All Grants

Education, Training & Certifications

University of Virginia, School of Medicine · 2009 M.D.